GlassScriptPhysician profile
Billy G Branch
NPI 1780975565
$3,826.75
in general payments reported to CMS, 2019-2025
36 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $492 · 2021: $787 · 2022: $894 · 2023: $646 · 2024: $397 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.88 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $632.90 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $560.70 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $357.47 | 2022-2024 | |
| Lilly USA, LLC | $287.25 | 2020-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.95 | 2019-2022 | |
| Pfizer INC. | $241.21 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $185.83 | 2020-2023 | Farxiga |
| Horizon Therapeutics Plc | $174.55 | 2019-2020 | |
| Esperion Therapeutics, INC. | $158.23 | 2020-2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $120.08 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $94.80 | 2019 | |
| Amgen INC. | $82.85 | 2024-2025 | Repatha, Repatha, Prolia |
| Abbott Laboratories | $60.49 | 2021-2024 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $50.02 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $47.37 | 2023-2024 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $41.69 | 2022-2023 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $40.68 | 2020-2022 | |
| Exact Sciences Corporation | $33.66 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $31.80 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $30.48 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $28.32 | 2022 | |
| Glaxosmithkline, LLC. | $28.16 | 2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.93 | 2022 | |
| Phathom Pharmaceuticals, INC. | $26.68 | 2024 | Voquezna |
| Philips North America LLC | $24.84 | 2022 | |
| Neurelis, INC. | $22.83 | 2023 | Valtoco |
| Xeris Pharmaceuticals, INC. | $22.16 | 2022 | |
| Supernus Pharmaceuticals, INC. | $22.09 | 2021 | |
| Eisai INC. | $20.99 | 2021 | |
| Sobi, INC | $20.29 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.45 | 2025 | Caplyta |
| Adlon Therapeutics L.P. | $16.60 | 2021 | |
| Avion Pharmaceuticals | $14.03 | 2020 | |
| Biogen, INC. | $13.99 | 2021 | |
| Allergan, INC. | $11.31 | 2020 | |
| Genentech USA, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.